How do you balance patient-centric considerations and the complexities cell and gene therapy manufacture and administration in a single suite of operational software?
- Ensuring regulatory and quality components are upheld
- Automating those elements so users don’t waste time flitting between systems and piles of paper
- Simplifying the complex
Below is a snippet of an interview with Heather Purvis and Carol Houts: ‘Manufacturing Advanced Therapies: Clinical Center Operational Considerations for Decentralized Manufacturing’ at Phacilitate’s Advanced Therapies Week.
You can watch the whole interview here.
